Results 161 to 170 of about 136,011 (340)

NKG2D‐mediated cytotoxicity improves after primary surgery for high‐grade serous ovarian cancer

American Journal of Reproductive Immunology, Volume 89, Issue 1, January 2023., 2023
Abstract Problem Tumors compromise the patients’ immune system to promote their own survival. We have previously reported that HGSC exosomes play a central role, downregulating NKG2D cytotoxicity. Primary surgery's effect on tumor exosomes and NKG2D cytotoxicity in HGSC patients has not been studied before.
Pernilla Israelsson, Emma Björk, Ivan Nagaev, Olga Nagaeva, Eva Lundin, Lucia Mincheva‐Nilsson, Ulrika Ottander   +6 more
wiley   +1 more source

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

British Journal of Cancer, 2020
Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab plus FOLFIRI in KRAS wild-type metastatic colorectal cancer (mCRC) in FIRE-3, but no corresponding benefit was found for progression-free survival.
V. Heinemann, L. V. von Weikersthal, T. Decker, A. Kiani, F. Kaiser, S. Al-Batran, T. Heintges, C. Lerchenmüller, C. Kahl, G. Seipelt, F. Kullmann, M. Moehler, W. Scheithauer, S. Held, L. Miller-Phillips, D. Modest, A. Jung, T. Kirchner, S. Stintzing   +18 more
semanticscholar   +1 more source

Machine learning for classification and quantification of monoclonal antibody preparations for cancer therapy [PDF]

arXiv, 2017
Monoclonal antibodies constitute one of the most important strategies to treat patients suffering from cancers such as hematological malignancies and solid tumors. In order to guarantee the quality of those preparations prepared at hospital, quality control has to be developed.
arxiv  

Multimodal treatment for local recurrent malignant gliomas: resurgery and/or reirradiation followed by chemotherapy [PDF]

, 2019
The therapeutic management of recurrent malignant gliomas (MGs) is not determined. Therefore, the efficacy of a multimodal approach and a combination systemic therapy was investigated.
Bianco, Vincenzo, ELENA REBUZZI, Sara, Ferrara, Carla, Fusto, Carmela, GIRON BERRIOS, JULIO RODRIGO, Grassi, Massimiliano, Pecorari, Silvia, Prelaj, Arsela, Salvati, Maurizio, Stati, Valeria, Tomao, Silverio   +10 more
core   +1 more source

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.

JAMA Oncology, 2020
Importance The combination of erlotinib and bevacizumab as initial treatment of epidermal growth factor receptor (EGFR [OMIM 131550])-mutant lung cancers improves progression-free survival (PFS) compared with erlotinib alone. Because osimertinib prolongs
H. Yu, A. Schoenfeld, A. Makhnin, R. Kim, H. Rizvi, D. Tsui, C. Falcon, B. Houck-Loomis, Fanli Meng, Julie L. Yang, Y. Tobi, G. Heller, Linda S Ahn, S. Hayes, R. Young, M. Arcila, M. Berger, J. Chaft, M. Ladanyi, Gregory Riely, M. Kris   +20 more
semanticscholar   +1 more source

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab [PDF]

, 2018
The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a
Angelini, F., Astone, A., Barba, M., Bertolini, I., Botti, C., Botticelli, A., Cassano, A., Ciliberto, G., De Angelis, C., Fabbri, M. A., Gamucci, T., Giordano, A., Grassadonia, A., Izzo, F., Lauro, L. D., Magnolfi, E., Marchetti, L., Marchetti, P., Maugeri-Sacca, M., Mazzotta, M., Mentuccia, L., Michelotti, A., Moscetti, L., Natoli, C., Pizzuti, L., Rossi, E., Sarobba, M. G., Sergi, D., Sini, V., Sperduti, I., Tomao, S., Vaccaro, Andrea, Vici, P.   +32 more
core   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Evaluation of the association between bevacizumab concentration and clinical outcomes in patients with breast cancer brain metastasis

Heliyon
Bevacizumab is widely used in various clinical indications, but investigations into its optimal dosage for treating CNS metastases remain limited. The BEEP regimen, comprising bevacizumab, etoposide, and cisplatin, has recently demonstrated promising ...
Chih-Ning Cheng, Yun-Jung Tsai, Huai-Hsuan Chiu, Tom Wei-Wu Chen, Ching-Hung Lin, Yen-Sheng Lu, Ching-Hua Kuo   +6 more
doaj  

Bevacizumab for the Treatment of Recurrent Glioblastoma

Clinical Medicine Insights: Oncology, 2011
Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death.
Marc C. Chamberlain
doaj   +1 more source

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. [PDF]

, 2017
BackgroundAdjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in ...
Adjei, Alex A, Aisner, Seena C, Butts, Charles, Chapman, Andrew E, Dahlberg, Suzanne E, ECOG-ACRIN, Evans, Tracey, Gandara, David R, Graziano, Stephen L, Horn, Leora, Kasbari, Samer S, Keller, Steven M, Leighl, Natasha B, McDermott, Sean R, Patel, Jyoti D, Perez-Soler, Roman, Ramalingam, Suresh S, Rothman, Jan M, Sborov, Mark D, Schiller, Joan H, Shafqat, Atif, Tester, William J, Traynor, Anne M, Wakelee, Heather A   +23 more
core   +1 more source